IV med may fight chemotherapy-resistant cancers
CT-2584, a novel small-molecule, anti-cancer, anti-antigenic drug from Seattle-based Cell Therapeutics, has completed a Phase I clinical trial with promising results.
The drug is administered intravenously over six hours for three consecutive days, followed by 18 days with no infusion of CT-2584. If no dose-limiting toxicities are observed during this first cycle, a second cycle is administered. Patients whose cancers have stopped progressing or who demonstrate reduced tumor size after the second cycle are eligible for up to six cycles of the drug.
Of 50 patients enrolled in trials in both the United States and England, 35 were evaluable for tumor response, having completed two cycles. Of these patients, cancer stabilized in 10, and seven are still alive after 10 months following treatment.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content